Olaparib 是一种 PARP 抑制剂，对 PARP1 和 PARP2 具有高亲和力，IC50 值分别为 5 nM 和 1 nM。Olaparib 具有抗肿瘤作用，可用于 BRCA 突变相关癌症的研究。

Veliparib（ABT-888）是一种强效的PARP抑制剂，抑制PARP1和PARP2的Ki值分别为5.2 nM和2.9 nM。

Talazoparib (BMN-673) 是一种高效、口服活性的PARP1/2抑制剂，对PARP1和PARP2的Ki值分别为1.2 nM和0.87 nM。它具有抗肿瘤活性。

A-966492 is a potent inhibitor of PARP1 and PARP2 with Ki of 1 nM and 1.5 nM, respectively.

Niraparib（MK-4827）是一种高效、口服生物利用度的PARP1和PARP2抑制剂，其IC50分别为3.8 nM和2.1 nM。尼拉帕尼抑制DNA损伤修复，激活凋亡，并显示出抗肿瘤活性。

UPF 1069 is a selective PARP2 inhibitor with IC50 of 0.3 μM, which is ~27-fold selective against PARP1.

ME0328 is a potent and selective PARP inhibitor with IC50 of 0.89 μM for PARP3, about 7-fold selectivity over PARP1.

E7449 is an orally bioavailable, potent, small molecule inhibitor of PARP1 and PARP2 and enhances the efficacy of radiotherapy and chemotherapy and has potent single agent anticancer activity in BRCA-deficient tumors.

Niraparib tosylate (MK-4827 tosylate)是一种高效且口服可用的PARP1和PARP2抑制剂，IC50值分别为3.8 nM和2.1 nM。尼拉帕利甲苯磺酸盐抑制DNA损伤修复，激活凋亡，并显示出抗肿瘤活性。

BSI-201 is a PARP1 inhibitor with demonstrated effectiveness in triple-negative breast cancer (TNBC).

AG14361 is a potent inhibitor of PARP1 with Ki of < 5 nM.

NMS-P118 is a potent, orally available, and highly selective PARP-1 inhibitor for cancer therapy with an IC50 of 0.04 μM in HeLa cell.